Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) Bundle
A Brief History of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd, founded in 1998, is a prominent player in the production of biochemical and pharmaceutical products. The company has established itself as a leader in both domestic and international markets, focusing on the development, manufacturing, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs).
The company was listed on the Shenzhen Stock Exchange in 2018 under the ticker symbol 002626. This significant milestone allowed King-Friend to accelerate its growth, invest in research and development, and enhance its production capabilities.
Over the years, the company has expanded its product line, which now includes over 100 different APIs and intermediates. King-Friend serves a diverse range of industries, including pharmaceuticals, agriculture, and animal health.
As of 2021, Nanjing King-Friend reported a revenue of approximately 1.2 billion CNY (around 185 million USD), reflecting a year-over-year increase of 15%. Their net profit for the same year was approximately 280 million CNY (around 43 million USD), showcasing strong profitability in a competitive market.
The company has also made substantial investments in research and development, allocating around 5% of its annual revenue toward R&D initiatives aimed at innovation and product enhancement. King-Friend has developed several patented technologies, establishing a robust pipeline of new products for future growth.
| Year | Revenue (CNY) | Net Profit (CNY) | R&D Investment (CNY) | Key Product Releases |
|---|---|---|---|---|
| 2018 | 800 million | 150 million | 40 million | Product A, Product B |
| 2019 | 900 million | 170 million | 45 million | Product C, Product D |
| 2020 | 1 billion | 230 million | 50 million | Product E, Product F |
| 2021 | 1.2 billion | 280 million | 60 million | Product G, Product H |
In terms of international presence, King-Friend has established partnerships with various global pharmaceutical firms to distribute its products worldwide. The company has received certifications from the FDA, EMA, and other regulatory bodies, enabling it to cater to a broader market.
As of 2023, Nanjing King-Friend is increasing its focus on sustainability and environmentally friendly practices. The company has set ambitious targets to reduce emissions by 30% over the next five years while maintaining production efficiency and output levels.
Furthermore, the stock performance of King-Friend has shown resilience, with shares appreciating by approximately 40% over the last three years. This uptick reflects investor confidence in the company's innovative capabilities and strategic direction.
Overall, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd has positioned itself for continued growth through strategic investments, product diversification, and expanding its global footprint. Its commitment to quality and innovation remains at the core of its operations and future endeavors.
A Who Owns Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd is a publicly traded company listed on the Shenzhen Stock Exchange under the ticker symbol 002662. The firm specializes in the production and supply of various biochemical products and pharmaceuticals. As of the latest reports, the company has experienced significant growth driven by its strategic focus on the pharmaceutical and biotech sectors.
Ownership of Nanjing King-Friend is divided among various institutional and individual shareholders. As of the end of 2022, the top shareholders are as follows:
| Shareholder Type | Percentage of Ownership | Number of Shares |
|---|---|---|
| Institutional Investors | 45% | 450 million |
| Individual Shareholders | 35% | 350 million |
| Company Insiders | 15% | 150 million |
| Other Investors | 5% | 50 million |
The largest institutional investor is the China Securities Finance Corporation Limited, holding approximately 15% of the shares, translating to about 150 million shares. Other significant institutional shareholders include numerous mutual funds and investment firms focused on the healthcare sector.
The company’s total outstanding shares are reported at 1 billion, with a current market capitalization of approximately ¥10 billion (around $1.5 billion USD) as of October 2023.
In its recent financial disclosures, Nanjing King-Friend reported a revenue of ¥2.5 billion for the fiscal year ending December 2022, a growth of 20% compared to the previous year. The net profit for the same period was approximately ¥300 million, showing a profit margin of 12%.
The shares of Nanjing King-Friend have exhibited volatility with a 52-week range of ¥8 to ¥15. The recent stock price, as of October 2023, was recorded at ¥10, reflecting a P/E ratio of approximately 33.33.
The governance of the company is overseen by a board of directors, primarily composed of individuals with extensive backgrounds in pharmaceuticals and biotechnology. The board includes members representing major stakeholders, ensuring a balance of interests between institutional investors and company management.
In summary, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd maintains a diverse ownership structure with substantial backing from institutional investors, coupled with solid financial performance that positions it well for future growth in the pharmaceutical industry.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Mission Statement
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd specializes in the development and manufacturing of high-quality pharmaceutical and biochemical products. The mission of the company centers around the commitment to enhance patient health by providing innovative therapeutic solutions while maintaining the highest standards in quality and compliance.
The company aims to leverage cutting-edge technology and expertise in the pharmaceutical industry to meet the growing demands for advanced healthcare solutions and contribute to global health improvements. This commitment is reflected in their focus on research and development, emphasizing the importance of adhering to rigorous scientific standards.
Strategic Objectives
- To innovate in the field of biochemistry for health improvement.
- To expand international market presence while ensuring compliance with global regulatory standards.
- To achieve sustainable growth and profitability through cutting-edge research initiatives.
- To maintain strong partnerships with healthcare providers and research institutions.
Financial Overview
- To innovate in the field of biochemistry for health improvement.
- To expand international market presence while ensuring compliance with global regulatory standards.
- To achieve sustainable growth and profitability through cutting-edge research initiatives.
- To maintain strong partnerships with healthcare providers and research institutions.
Financial Overview
In the fiscal year 2022, Nanjing King-Friend reported a total revenue of ¥1.2 billion, representing a growth of 15% compared to the previous year. The company’s net profit for the same period was approximately ¥200 million, with a net profit margin of 16.67%.
Recent Performance Metrics
| Metric | 2022 | 2021 |
|---|---|---|
| Total Revenue | ¥1.2 billion | ¥1.04 billion |
| Net Profit | ¥200 million | ¥150 million |
| Net Profit Margin | 16.67% | 14.42% |
| R&D Investment | ¥150 million | ¥100 million |
The company's focus on research and development is evident from their increased investment in R&D, which amounted to ¥150 million in 2022. This represents an increase of 50% year-over-year, indicating a strong commitment to improving product offerings and staying competitive in the market.
Market Positioning
Nanjing King-Friend operates in the competitive landscape of the pharmaceutical industry, focusing on the production of APIs (Active Pharmaceutical Ingredients) and intermediates. As of 2023, the company holds approximately 5% market share in the Chinese pharmaceutical API market, which is valued at around ¥100 billion.
Regional expansions, along with strategic partnerships, have been pivotal in positioning Nanjing King-Friend as a notable player in this sector. Their mission aligns with the increasing global market for pharmaceuticals projected to reach $1.5 trillion by 2023, influenced heavily by an aging population and rising health issues.
Commitment to Sustainability
Nanjing King-Friend has also integrated sustainability into its mission statement, focusing on environmentally friendly practices and sustainable sourcing of materials. In 2022, the company reduced its carbon footprint by 10%, contributing to its goal of achieving carbon neutrality by 2030.
This approach not only addresses environmental concerns but also aligns with consumer preferences that increasingly favor sustainable products, representing a growing segment in the pharmaceutical industry.
How Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Works
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd, founded in 1998, specializes in the research, development, production, and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). As of 2023, the company is publicly traded on the Shanghai Stock Exchange under the ticker symbol 002626.
The core focus of King-Friend Biochemical is on the production of amino acids, which are crucial in various pharmaceutical and nutraceutical applications. The company operates multiple production plants in Jiangsu Province, which feature advanced technologies and comply with international quality standards.
In 2022, Nanjing King-Friend reported a revenue of approximately 2.95 billion CNY, representing a year-on-year increase of 12.5%. The net profit for the same year totaled around 350 million CNY, marking a net profit margin of approximately 11.86%.
The company's product portfolio includes:
- Amino acids
- Peptides
- Intermediates for antibiotics
- Vitamin series
King-Friend Biochemical caters to both domestic and international markets, exporting to over 30 countries globally, including the United States, Germany, and Japan. In 2023, exports accounted for approximately 40% of the total sales revenue.
The company places a significant emphasis on research and development, allocating around 8% of its revenue towards R&D efforts annually. This investment has resulted in a robust pipeline of products and a commitment to innovation within the pharmaceutical sector.
Financial Performance Overview
| Year | Revenue (CNY) | Net Profit (CNY) | Net Profit Margin (%) | R&D Investment (CNY) |
|---|---|---|---|---|
| 2020 | 2.38 billion | 280 million | 11.76 | 190 million |
| 2021 | 2.63 billion | 310 million | 11.80 | 210 million |
| 2022 | 2.95 billion | 350 million | 11.86 | 240 million |
The company’s commitment to quality is demonstrated by its compliance with Good Manufacturing Practices (GMP) and certifications from various international bodies. This focus on quality assurance significantly enhances its competitive edge in the global market.
Furthermore, King-Friend is actively pursuing diversification strategies, including the development of new products and expansion into emerging markets. In 2023, the company announced plans to invest 500 million CNY in the expansion of its facilities to increase production capacity and enhance efficiency.
Market trends indicate that the demand for pharmaceutical intermediates is expected to rise, driven by an aging population and increasing health awareness. King-Friend Biochemical is well-positioned to capitalize on these trends, given its established market presence and ongoing investment in R&D.
Overall, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd operates with a solid growth strategy, focusing on innovation, quality, and market expansion. The company is poised to continue its upward trajectory in the increasingly competitive pharmaceutical landscape.
How Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Makes Money
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd primarily operates in the biochemical pharmaceutical industry, focusing on the research, development, and production of active pharmaceutical ingredients (APIs), as well as finished dosage forms. The company derives its revenue through several core segments:
1. Active Pharmaceutical Ingredients (APIs)
Nanjing King-Friend is a leading producer of various APIs, which are critical components in pharmaceutical products. In 2022, the revenue from APIs accounted for approximately 65% of the company’s total sales, generating around RMB 1.3 billion in income. The key APIs produced include:
- Metformin
- Ibuprofen
- Orlistat
2. Finished Dosage Forms
The company also manufactures finished dosage forms such as tablets, capsules, and injections. In the same fiscal year, finished dosage forms contributed to about 30% of total revenue, with sales reaching approximately RMB 780 million.
3. Export Markets
International sales play a significant role in revenue generation, accounting for approximately 40% of total sales. In 2022, exports totaled around RMB 600 million, with major markets including:
- North America
- Europe
- Asia-Pacific
4. Research and Development
King-Friend invests heavily in R&D to maintain a competitive edge and introduce new products. In 2022, the company allocated around RMB 150 million to R&D activities, which is approximately 8% of its total revenue. This investment aims to expand its product portfolio and enhance existing formulations.
5. Financial Performance Overview
| Year | Total Revenue (RMB) | API Revenue (RMB) | Finished Dosage Forms Revenue (RMB) | Export Revenue (RMB) | R&D Investment (RMB) |
|---|---|---|---|---|---|
| 2022 | RMB 2 billion | RMB 1.3 billion | RMB 780 million | RMB 600 million | RMB 150 million |
| 2021 | RMB 1.9 billion | RMB 1.25 billion | RMB 700 million | RMB 550 million | RMB 130 million |
| 2020 | RMB 1.8 billion | RMB 1.1 billion | RMB 600 million | RMB 500 million | RMB 120 million |
6. Market Trends and Future Prospects
The global pharmaceutical market is expected to grow at a CAGR of 5.8% from 2023 to 2028. As a key player in this sector, Nanjing King-Friend is positioned to benefit from the increasing demand for innovative APIs and pharmaceuticals. The company continues to explore partnerships and collaborations to enhance its market reach and operational efficiency.
7. Regulatory Compliance and Quality Control
Compliance with international regulations, such as those set by the FDA and EMA, ensures that King-Friend can effectively market its products globally. The company has invested in quality control systems, reflecting an increase in operational costs by approximately 15% in 2022 compared to 2021.
Nanjing King-Friend’s business model, focusing on API production and finished dosage forms, along with robust R&D investments and global market engagement, underpins its revenue generation strategies in the competitive biochemical pharmaceutical landscape.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.